Ivonescimab Clinical Trials
29 recruitingDrug
Phase 228Phase 16
Showing 1–20 of 29 trials
Recruiting
Phase 2
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
TNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast CarcinomaTNBC
Cedars-Sinai Medical Center34 enrolled4 locationsNCT07017673
Recruiting
Phase 2
A Study of Ivonescimab in People With Leiomyosarcoma
Leiomyosarcoma
Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT07516925
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled5 locationsNCT07397338
Recruiting
Phase 1
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd288 enrolled1 locationNCT06868732
Recruiting
Phase 2
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Cervical CancerEndometrial Cancer
Memorial Sloan Kettering Cancer Center50 enrolled7 locationsNCT06925724
Recruiting
Phase 2
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
M.D. Anderson Cancer Center24 enrolled1 locationNCT06567314
Recruiting
Phase 2
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Pleural Mesotheliomas
Intergroupe Francophone de Cancerologie Thoracique38 enrolled20 locationsNCT06840834
Recruiting
Phase 2
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Second Xiangya Hospital of Central South University70 enrolled20 locationsNCT06951646
Recruiting
Phase 2
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Esophagus CancerStomach CancerStomach Cancer Stage IV
Massachusetts General Hospital40 enrolled2 locationsNCT07070466
Recruiting
Phase 2
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
IvonescimabClear Cell Renal Carcinoma
M.D. Anderson Cancer Center40 enrolled1 locationNCT06940518
Recruiting
Phase 1Phase 2
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Glioblastoma
M.D. Anderson Cancer Center45 enrolled2 locationsNCT06672575
Recruiting
Phase 2
ctDNA-guided Treatment Decision-making
Metastatic Breast Cancer ( HER2 Negative)ctDNA
Fudan University122 enrolled1 locationNCT07394218
Recruiting
Phase 1Phase 2
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
Advanced Malignant Tumors
Shanghai JMT-Bio Inc.436 enrolled1 locationNCT06877650
Recruiting
Phase 2
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
Advanced Head and Neck Squamous Cell CarcinomaResectable Head and Neck Squamous Cell CarcinomaStage II Head and Neck Cutaneous Squamous Cell Carcinoma+2 more
University of Michigan Rogel Cancer Center28 enrolled1 locationNCT07094685
Recruiting
Phase 2
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Metastatic Gastric AdenocarcinomaAdvanced Esophageal AdenocarcinomaAdvanced Gastric Adenocarcinoma+1 more
UNICANCER88 enrolled4 locationsNCT06846346
Recruiting
Phase 2
A Study of Ivonescimab in First-Line ES-SCLC
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Akeso180 enrolled3 locationsNCT07245446
Recruiting
Phase 2
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Biliary Tract Cancer
UNICANCER72 enrolled3 locationsNCT06529718
Recruiting
Phase 1Phase 2
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.260 enrolled1 locationNCT07208773
Recruiting
Phase 2
IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
Metastatic Endocrine RefractoryTriple Negative Invasive Lobular Carcinoma
M.D. Anderson Cancer Center29 enrolled1 locationNCT07229417
Recruiting
Phase 2
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
M.D. Anderson Cancer Center90 enrolled1 locationNCT06959550